Aerobic Training in Supporting Patients with Solid Tumors before Surgery, PRESTO 1 study

Inclusion Criteria

• PHASE 0 (PROOF OF CONCEPT): Patients with one of the following: * Early-stage breast cancer having completed participation in Institutional Review Board (IRB)# 15-147 * Diagnosed with the prespecified solid tumors: endometrial, breast, or prostate cancer * Underwent a diagnostic lung biopsy within 14 days prior to enrollment
• PHASE 0 (PROOF OF CONCEPT): Age > 18 years
• PHASE 0 (PROOF OF CONCEPT): Body mass index (BMI) =< 40
• PHASE 0 (PROOF OF CONCEPT): Has >= 20 mg of normal lung and suspicious lung tissue from the standard of care diagnostic biopsy available for snap freezing and single-cell sequencing (lung patients only)
• PHASE 0 (PROOF OF CONCEPT): At least a 2-week window from study enrollment to scheduled surgical resection (patients with prespecified solid tumors only).
• PHASE 0 (PROOF OF CONCEPT): Performing less than 30 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self report. If > 30 minutes but less than 90 minutes, patients may be eligible, at the discretion of the principal investigator (PI).
• PHASE 0 (PROOF OF CONCEPT): Cleared for exercise participation as per screening clearance via Physical Activity Readiness Questionnaire for Everyone (PAR-Q+).
• PHASE 0 (PROOF OF CONCEPT): Willingness to comply with all study-related procedures.
• PHASE IA (DOSE-FINDING/ESCALATION): Patients with operable untreated prostate cancer scheduled for surgery
• PHASE IA (DOSE-FINDING/ESCALATION): At least a 2-week window from study enrollment to scheduled surgical resection.
• PHASE IA (DOSE-FINDING/ESCALATION): BMI =< 40. * BMI > 40, patients may be eligible, at the discretion of the principal investigator (PI)
• PHASE IA (DOSE-FINDING/ESCALATION): Performing =< 30 minutes of structured moderate-intensity or strenuous-intensity exercise per week, as evaluation by self report. * If > 30 minutes but less than 90 minutes, patients may be eligible, at the discretion of the PI
• PHASE IA (DOSE-FINDING/ESCALATION): Cleared for exercise participation as per screening clearance via PAR-Q+
• PHASE IA (DOSE-FINDING/ESCALATION): Willingness to comply with all study-related procedures

Exclusion Criteria

• Use of any selective estrogen receptor modulator or aromatase inhibitor within 6 months of study entry, including, but not limited to: tamoxifen, raloxifene, arzoxifene, acolbifene, anastrozole, exemestane, and letrozole (for preoperative breast, endometrial, and prostate patients in Phase 0 only).
• Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound the effect of exercise on study outcomes.
• Men receiving gonadotropin-releasing hormone (GNRH) agonists and antagonists as well as any antiandrogens.
• Any neoadjuvant anticancer treatment of any kind for the cancer of interest.
• Any other diagnosis of invasive cancer currently requiring active treatment.
• Any history of systemic anticancer therapy.
• Metastatic malignancy of any kind.
• Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation.